BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Biocon Ltd. reported strong revenues driven by all three segments.
Revenues grew 31% YoY to Rs 2409 crore driven by biosimilars growing 48% YoY to Rs 982 crore on back of improved performance across geographies and market share gains by interchangeable bGlargine in the U.S.
Biocon's research services segment grew 15% YoY to Rs 758 crore driven by strong quarter for development services as it caught up on postponed projects in addition to planned work while generic sales increased 26% YoY to Rs 717 crore driven by contribution from new launch of Everolimus in U.S., uptick in active pharma ingredient business and normalisation of supply challenges.
Ebitda margins came in-line with our expectations amid a 91 basis points YoY improvement to 24.6% mainly due to decline in gross margin (down 296 bps YoY) at 65.6% and higher other expenditure being offset by lower employee cost.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR